The global creatinine assay kits market is expected to reach USD 245.4 million by 2022 from USD 189.6 million in 2017, at a CAGR of 5.3%. This market is experiencing significant growth due to increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=73499229

The creatinine assay kits market is segmented on the basis of type, type of sample, and region. By type, the market is segmented into Jaffe’s kinetic test kits, Creatinine-PAP test kits, and ELISA test kits. In 2017, the creatinine-PAP test kits segment is expected to witness the highest CAGR over the forecast period. The enzymatic method has several advantages over the conventional kinetic Jaffe’s method. These include high accuracy and specificity, low sample volume, and lack of interfering substances. These advantages make the enzymatic method ideal for creatinine measurement.

The creatinine assay kits market, by type of sample is segmented into blood/serum, urine, and other samples. The blood/serum segment is expected to witness the fastest growth over the forecast period, as it ensures greater result accuracy. Routine physical examinations such as basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) also include serum creatinine testing. Most newly developed creatinine measurement kits are based on the analysis of creatinine in blood samples owing to its accuracy in inferring creatinine concentration. These are the major factors responsible for the increasing adoption of this sample type.

Among the four regional segments covered in the creatinine assay kits market—North America, Europe, Asia, and the Rest of the World (RoW), North America accounted for the largest share of the global creatinine assay kits market in 2017. Asia is expected to grow at the fastest CAGR during the forecast period. The markets in Asian countries are driven by factors such as the growing prevalence of CKD, rising awareness towards preventive healthcare, improving healthcare infrastructure, and growing focus of market players on addressing demands in these countries.